Alendronic acid versus teriparatide in women with postmenopausal osteoporosis

Trial Profile

Alendronic acid versus teriparatide in women with postmenopausal osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2011

At a glance

  • Drugs Alendronic acid; Teriparatide
  • Indications Fracture; Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Acronyms FACT
  • Sponsors Eli Lilly
  • Most Recent Events

    • 20 Dec 2011 Not official study title
    • 08 Nov 2011 Results of an analysis of bone remodelling parameters (n=21) presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
    • 05 Nov 2010 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top